Vorasidenib

Voradisenib
Clinical data
License data	US DailyMed: Vorasidenib;
Drug class	Antineoplastic agent
Identifiers
	IUPAC name 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine;
PubChem CID	117817422;
Chemical and physical data
Formula	C14H13ClF6N6
Molar mass	414.74 g·mol−1

Vorasidenib is an anti-cancer medication for the treatment of low-grade Glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer. ^[1]In a phase-III-trial it was shown to prolong progression-free survival in patients with IDH1- or IDH2-Mutant Low-Grade Glioma.^[2]

References

^ "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.{{cite web}}: CS1 maint: url-status (link)
^ Ingo K. Mellinghoff; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690